Physician profile
David C Crabtree
NPI 1487605291
$13,651.31
in general payments reported to CMS, 2019-2025
54 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $1,688 · 2021: $2,154 · 2022: $2,327 · 2023: $2,378 · 2024: $1,701 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,600 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,600.35 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,360.76 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,769.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $1,051.02 | 2019-2025 | Hizentra, Haegarda |
| Mylan Specialty L.P. | $919.22 | 2019-2024 | Yupelri |
| Optinose US, INC. | $867.47 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $802.11 | 2019-2025 | Ofev |
| Genzyme Corporation | $775.48 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $740.51 | 2021-2025 | Glassia, Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $584.88 | 2019-2025 | Dupixent |
| Amgen INC. | $445.54 | 2019-2025 | Tezspire, Repatha, Otezla |
| Insmed, INC. | $424.59 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $416.27 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Octapharma USA, INC. | $320.10 | 2020-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $303.78 | 2019-2024 | Xolair |
| Inspire Medical Systems, INC. | $142.39 | 2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.